Amount of funding: Direct costs budgeted for the entire period of performance will not exceed $500,000.
Purpose: The intent of the FY22 ALSRP Clinical Biomarker Development Award (CBDA) is to maximize clinical ALS resources and biorepositories to better define subtypes, assess prognosis, or predict therapeutic response and to improve value of clinical trials. Applications should focus on the development and improvement of clinical biomarkers to enrich clinical trials in ALS. Biomarkers may be predictive/cohort-selective, prognostic, and/or pharmacodynamic. Biomarker development or data analysis can be relevant to a specific therapeutic or class of therapeutics, or to a specific type of ALS (such as a particular genetic mutation) and does not have to broadly apply to all patients.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be PI. Early-career investigators and/or early-career physician scientists (defined as independent, nonmentored investigators within 10 years of their last training position e.g., postdoctoral fellowship, medical residency, clinical fellowship as of the application submission deadline) are encouraged to apply.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
REQUIRED Pre-Application (Pre-Proposal) Deadline: April 29, 2022 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) Deadline: July 21, 2022
Application Submission Deadline: July 28, 2022 via grants.gov